Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since results from one of the first clinical trials of such a therapeutic approach in patients with NSCLC were reported in 2018 (ref. 19), the efficacy and safety of neoadjuvant ICIs have been firmly established in multiple tumour types, with FDA approvals for two indications (NSCLC20,120 and triple-negative breast cancer8).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [19]
Citations
Cites
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Signaling Through OX40 Enhances Antitumor Immunity
Jensen, S. M., Maston, L. D., Gough, M. J., Ruby, C. E., Redmond, W. L., Crittenden, M., Li, Y., Puri, S., Poehlein, C. H., Morris, N., et al. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.013 · Cited by 146
Imbalance of dendritic cell co-stimulation in COPD
Stoll, P., Ulrich, M., Bratke, K., Garbe, K., Virchow, J. C., Jr., & Lommatzsch, M. (2015) · Respiratory Research · doi:10.1186/s12931-015-0174-x · Cited by 36
Cited by
Items 101–200 of 291
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Qiu, B., Cai, K., Chen, C., Chen, J., Chen, K., Chen, Q., Cheng, C., Dai, T., Fan, J., Fan, Z., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-634 · Cited by 22
Borden, E. S., Ghafoor, S., Buetow, K. H., LaFleur, B., Wilson, M. A., & Hastings, K. T. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100700 · Cited by 22
Parks, O. B., Eddens, T. J., Sojati, J., Lan, J., Zhang, Y., Oury, T. D., Ramsey, M. J., Erickson, J. J., Byersdorfer, C. A., & Williams, J. V. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00365-5 · Cited by 19
Liquid biopsy for lung cancer immunotherapy (Review)
Cai, L., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10166 · Cited by 26
Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer
Chen, Y., Zhang, L., Yan, B., Zeng, Z., Hui, Z., Zhang, R., Ren, X., & You, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-539 · Cited by 20
Remón, J., Menis, J., Lévy, A., Ruysscher, D. D., & Hendriks, L. E. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1065 · Cited by 19
Liu, Y., Wang, H., Zhao, X., Zhang, J., Zhao, Z., Lian, X., Zhang, J., Kong, F., Hu, T., Wang, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3115 · Cited by 18
Bernicker, E., & Quigley, E. M. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.016 · Cited by 20
Immunotherapy in head and neck squamous cell carcinoma: a narrative review
Sharon, S., & Bell, R. B. (2022) · Frontiers of Oral and Maxillofacial Medicine · doi:10.21037/fomm-21-48 · Cited by 19
Lai, Y., Chang, W., Chen, C., Wang, C.-L., Lin, Y., Ho, M.-M., Cheng, C.-Y., Huang, P., Hsu, C., & Lin, G. (2019) · Acta Radiologica · doi:10.1177/0284185119887588 · Cited by 18
Xu, H., Li, N., Wang, G., & Cao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110028 · Cited by 19
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
Segovia, M., Russo, S., Girotti, M. R., Rabinovich, G. A., & Hill, M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13433 · Cited by 20
Expert consensus on perioperative treatment for non-small cell lung cancer
Duan, J., Tan, F., Bi, N., Chen, C., Chen, K., Cheng, Y., Chu, Q., Ge, D., Hu, J., Huang, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-527 · Cited by 19
Sun, X., Lyu, J., Yang, M., Lin, Y., Wu, K., Liu, K., Li, A., Shuai, X., Cai, K., Wang, Z., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16041-x · Cited by 18
Ge, S., & Huang, C. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1664 · Cited by 17
Hattori, A., Matsunaga, T., Takamochi, K., Oh, S., & Suzuki, K. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.03.232 · Cited by 15
Chen, J., Han, Y., Hu, Y., Feng, X., Meng, X., Guo, S., Sun, C., Chen, G., & Li, K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067767 · Cited by 17
Zheng, Y., Feng, B., Chen, J., & You, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273220 · Cited by 17
“These rates were signi fi cantly higher than those for neoadjuvant chemotherapy (pooled pCR of 0.04) and neoadjuvant immunotherapy (pCR of no more than 0.10) reported in previous studies (7, 15, 16).”
InfluentialYang, Z., Liu, M.-N., Yu, J., Yang, Y., Chen, T., Han, Y., Zhu, L., Zhao, J., Fu, X., & Cai, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-896 · Cited by 17
Sepesi, B., Cascone, T., Chun, S. G., Altan, M., & Le, X. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.06.009 · Cited by 15
“The first trial testing neoadjuvant ICB enrolled 21 patients with resectable stages IB– IIIA NSCLC.18 Patients received 2 doses of neoadjuvant nivolumab followed by surgery.”
BackgroundMethodInfluentialChen, C., Wang, Q., Zhou, D., 黄晓洁, Zhao, Z., Qian, B., Wu, F., Chen, J., Liang, Q., Jiang, Y., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-023-01422-y · Cited by 16
Dulguun, E. (2023) · Journal Dimensie Management and Public Sector · doi:10.48173/jdmps.v4i4.243 · Cited by 18
Magnetite nanoparticles: an emerging adjunctive tool for the improvement of cancer immunotherapy
Jungcharoen, P., Thivakorakot, K., Thientanukij, N., Kosachunhanun, N., Vichapattana, C., Panaampon, J., & Saengboonmee, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00220 · Cited by 13
Ali, W. A. S., Hui, P., Ma, Y., Wu, Y., Zhang, Y., Chen, Y., Hong, S., Yang, Y., Huang, Y., Zhao, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1702 · Cited by 13
Shao, L., & Lou, G. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1192 · Cited by 14
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Conroy, M. R., Dennehy, C., & Forde, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107314 · Cited by 13
Immunotherapy for Neuro-Oncology
Majd, N., Dasgupta, P., & de Groot, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_8 · Cited by 16
Induction treatment in patients with stage III non-small cell lung cancer
Palmero, R., Vilariño, N., Navarro-Martín, A., & Nadal, E. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-420 · Cited by 13
Calvo, V., Aliaga, C., Carracedo, C. F., & Provencio, M. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-515 · Cited by 16
Hu, H., Xu, H., Lu, F., Zhang, J., Xu, L., Xu, S., Jiang, H., Zeng, Q., Chen, E., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.627436 · Cited by 12
“In addition to targeted drugs, immune drugs are also emerging and becoming popular therapeutic drugs, such as Nivolumab and Ipilimumab (Yang et al., 2018; Pinto et al., 2019).”
BackgroundSelf-citationZhang, K., Cai, J., Lu, C., Zhu, Q., Zhan, C., Shen, Y., Gu, J., & Ge, D. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-428 · Cited by 12
Chiari, R., Sidoni, A., & Metro, G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.22 · Cited by 12
Liao, H., Luo, X., Liang, Y., Wan, R.-P., & Xu, M. M. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-240 · Cited by 12
Mano, R., Düzgöl, C., Ganat, M., Goldman, D. A., Blum, K. A., Silagy, A. W., Walasek, A., Sánchez, A., DiNatale, R. G., Marcon, J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.07.019 · Cited by 12
“[21-23] Recent phase II trials in non-small-cell lung cancer and melanoma have demonstrated the feasibility and potential benefit of neoadjuvant immunotherapy.[3, 4] Current ongoing trials are evaluating the safety and benefit of neoadjuvant immunotherapy and combination treatments of tyrosine kinase inhibitors and im…”
BackgroundRecent advances in early stage lung cancer
Luna, J., Sotoca, A., Fernández, P., Miralles, C., & Pérez, A. R. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202102.010 · Cited by 18
Immunotherapy for Neuro-oncology
Majd, N., Dasgupta, P., & de Groot, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_7 · Cited by 11
Tang, X., Yang, Z.-Z., Kim, H. J., Anagnostou, T., Yu, Y., Wu, X., Chen, J., Krull, J. E., Wenzl, K., Mondello, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0977 · Cited by 11
Yin, W., Wang, W., Zou, C., Li, M., Chen, H., Meng, F., Dong, G., Wang, J., Yu, Q., Sun, M., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010016 · Cited by 11
“2023, 13, 16 10 of 11 MCV Mean corpusular volume Mg Magnesium NGS Next-generation sequencing NSCLC Non-small cell lung cancer NSE Neuron specific enolase OS Overall survival PCT Plateletocrit PD-1 Programed death-1 PLT Platelet count PN Pulmonary nodule RBC Red blood cell RDW Red cell volume distribution width ROC Rec…”
BackgroundSelf-citationJomrich, G., Kollmann, D., Ramazanova, D., Ristl, R., Grose, R. P., Ilhan‐Mutlu, A., Preusser, M., Fassnacht, C., Tsai, Y.-C., Guenova, E., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.08.016 · Cited by 12
Wu, Q., Xia, Y., Xiong, X., Duan, X., Pang, X., Zhang, F., Tang, S., Su, J., Wen, S., Mei, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1169608 · Cited by 14
“, 2020); 4) sustained clinical responses to the immunotherapy (Forde et al., 2018; Zhang and Zhang, 2020); and 5) fewer side effects than the traditional treatments (Tan S.”
BackgroundLi, B., Guo, Y. H., Yi, Y., Huang, Z., Ren, Y., Wang, H., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04489-6 · Cited by 12
Tao, X., Yuan, C., Zheng, D., Ye, T., Pan, Y., Zhang, Y., Xiang, J., Hu, H., Chen, H., & Sun, Y. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.03.42 · Cited by 10
Filipska, M., Pedraz‐Valdunciel, C., CHAIB-OUKADOUR, I., & Rosell, R. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1582635 · Cited by 10
Miller, A., & Manser, R. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-806 · Cited by 15
The 100 most cited articles on thoracic surgery management of lung cancer
Jin, K., Hu, Q., Xu, J., Wu, C., Hsin, M. K. Y., Zirafa, C. C., Novoa, N. M., Bongiolatti, S., Cerfolio, R. J., Shen, J., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.11.14 · Cited by 10
Scordamaglia, D., Talia, M., Zicarelli, A., Mondino, A. A., Rosis, S. D., Dio, M. D., Silvestri, F., Meliti, C., Cirillo, F., Francesco, E. M. D., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10307-w · Cited by 9
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Zhang, D., Huang, J., Zhang, C., Guan, Y., & Guo, Q. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.06.07 · Cited by 12
Ni, Y., Lei, J., Huang, W., Wang, J., Guo, H., Lv, F., Kang, S., Lan, K., & Jiang, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1092663 · Cited by 13
“Then, many recent clinical trials have assessed the value of the immunotherapies as perioperative treatments for operable NSCLC and demonstrated that perioperative immunotherapies decreased tumor stage, enhanced the rate of complete resection, and reduced recurrence after surgery (17).”
BackgroundNEDD1 overexpression increases cell proliferation, tumor immune escape, and drug resistance in LUAD
Zhuo, T., Wu, Z., Chen, S., Yang, C., Huang, H., Gan, J., Lyu, J., Xiao, J., Li, Z., Qin, S., et al. (2024) · Journal of Cancer · doi:10.7150/jca.91671 · Cited by 9
Zhao, R., Guan, X., Zhang, P., Liu, Y., Xu, Y., Sun, C., Qiu, S., Zhu, W., Yang, Z., & Wang, X. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05683-9 · Cited by 10
Cao, M., Fu, Y., Xiao, X., Wang, L., Tang, D., & Zhao, X. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7582 · Cited by 9
Zhao, D., Xu, L., Wu, J., She, Y., Su, H., Hou, L., Haoran, E., Zhang, L., Grossi, F., Subramanian, M. P., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-476 · Cited by 10
Self-citationBao, Z., Jia, N., Zhang, Z., Hou, C., Yao, B., & Li, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1528529 · Cited by 8
“The PCR rate for lung cancer patients is only 5-15% (36, 37).”
Si, X., Zheng, X., Tian, X., Wang, H., Xu, Y., Zhao, J., Chen, M., Zhong, W., Wang, M., Zhang, L., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14987 · Cited by 9
Zhu, Y., Tan, L., Luo, D., & Wang, X. (2024) · Diagnostics · doi:10.3390/diagnostics14060667 · Cited by 10
Zhang, N., Li, C., Zhao, Z., Jiang, B., Wang, W., Sun, F., Zhang, Y., & Zhu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1497004 · Cited by 9
Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
Xu, J., Wu, Y., Xu, Y., Qiu, Y., Li, X., Song, Y., & Zhang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802672 · Cited by 9
“Neoadjuvant ICIs plus adjuvant ICIs 68 (12-97) 0.”
BackgroundLi, S., Chu, X., Ye, L., Ni, J., & Zhu, Z. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-512 · Cited by 9
Cheng, X., Wang, L., & Zhang, Z. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-630 · Cited by 8
Zhou, H., Lin, L., Qin, T., Ren, W., Tan, Y., Yang, Q., Xu, H., Xie, X., Chen, Y., Liu, S., et al. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1022 · Cited by 7
Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
Montemuiño, S., Sánchez, S. M., Rodríguez, J. C., Vila, B. L., Herrero, E. L., Díaz, M. D. H., González, V. V.-B., Valladares, B. T., Barrón, B. V., Jimenez, F. J. M., et al. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202102.013 · Cited by 9
Liu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M., Yang, Z., Lim, R., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · immuneACCESS · doi:10.21417/sl2021crm · Cited by 7
Wang, X., Tan, W., Sheng, H., Zhou, W., Zheng, H., Huang, K., Lin, J., Guo, S., & Mao, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1660897 · Cited by 6
“While two independent clinical trials reported signi fi cant associations between pretreatment TMB levels and response to neoadjuvant immunotherapy (17, 18), another study found no correlation between TMB and nICT ef fi cacy (19).”
The intratumoral landscape of T cell receptor repertoire in esophageal squamous cell carcinoma
Yang, M., He, D., Sun, Y., Guo, Y., Ma, Y., Feng, L., & Liu, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05825-0 · Cited by 6
Chen, Z., Hu, B., Cai, K., Gao, H., Xian, Z., Zhang, S., Fang, Z., Zhou, Q., Ren, D., & Zou, Q. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04027-x · Cited by 7
Minervini, F., Kestenholz, P., Kocher, G. J., & Azenha, L. F. (2022) · AME Surgical Journal · doi:10.21037/asj-21-77 · Cited by 6
A Review of Immune Checkpoint Blockade for the General Surgeon
Baldwin, X. L., Spanheimer, P. M., & Downs‐Canner, S. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.08.040 · Cited by 7
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
Park, S., Lee, Y., Lee, J., Min, Y. W., Kim, H. K., Choi, J. Y., Jung, H. A., Choi, Y. S., Choi, Y., Shim, Y. M., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.897 · Cited by 7
Yang, J., Chen, Y., Zhang, X., Tong, Z., Weng, S., Zhu, N., & Yuan, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03846-8 · Cited by 6
Tian, Y., Huang, J., Li, C., Jiang, L., Lin, H., Lu, P., Luo, Q., & Yang, G. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3927 · Cited by 6
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology
DiNatale, R. G., Hakimi, A. A., & Chan, T. A.-T. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa203 · Cited by 7
Shinohara, S., Takahashi, Y., Masago, K., Matsushita, H., & Kuroda, H. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-957 · Cited by 7
Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors
Chew, H. Y., Dolcetti, R., & Simpson, F. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14338 · Cited by 6
Ren, Y., Tang, H., Zhang, J., She, Y., Sun, X., Xie, D., & Chen, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920973567 · Cited by 8
Franco, F., & Provencio, M. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.09.68 · Cited by 6
Li, R., Chen, J., Zhao, W., Liang, R., & Xiong, H. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02540-2 · Cited by 5
PD-1 Impairs CD8+ T Cell Granzyme B Production in Aged Mice during Acute Viral Respiratory Infection
Parks, O. B., Antos, D., Eddens, T. J., Walters, S., Johnson, M., Oury, T. D., Gottschalk, R. A., Erickson, J. J., & Williams, J. V. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300094 · Cited by 5
“Studies have previously shown that PD-1 blockade improves CD8 1 T cell function in chronic viral infection and cancer models (34, 35).”
A narrative review on perioperative systemic therapy in non-small cell lung cancer
Hsu, R. C., Arter, Z., Poei, D., & Benjamin, D. J. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00256 · Cited by 6
Wang, Y., Zhou, J., Peng, S., Cui, Z., Wang, W., Zeng, W., Qiu, T., & Liu, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1533556 · Cited by 7
Wang, Y., Peng, L., Zhao, M., Xiong, Y., Xue, J., Li, B., Huang, Z., Liu, X., Yang, X., Song, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-629 · Cited by 6
Self-citationImmunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients
Sau, S., & Iyer, A. K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.66 · Cited by 5
Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review
Wilson, K., Flood, M. P., Oh, D., Calvin, N., Michael, M., Ramsay, R. G., & Heriot, A. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10192-x · Cited by 5
Wen, T., Su, C., Xu, C., Wang, Y., Ma, T., Bai, Z., Zhang, H., & Liu, Z. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02765-9 · Cited by 5
Li, L., He, K., Zhou, T., Xu, Y., Pang, J., Yu, Q., Gao, Y., Shi, H., Zhu, H., Li, M., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13600 · Cited by 4
Ren, Q., Li, Q., Shao, C., Zhang, P., Hu, Z., Li, J., Wang, W. T., & Yu, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11249-8 · Cited by 5
Wilkinson, A. N. (2021) · Canadian Family Physician · doi:10.46747/cfp.6707512 · Cited by 4
Brave new world—new and emerging treatments for gastric cancer
Lynch, E., Duffy, A. G., & Kelly, R. J. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-13 · Cited by 4
Wang, Q., Chen, Q., Luo, J., Xu, N., Xu, M., Qiang, Y., Zhang, C., & Shen, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1239451 · Cited by 4
Wang, G., Wang, G., Zhao, K., Sui, A.-F., Wang, L., Xu, Y., Qu, N., Ma, X., & Deng, H. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-04904-8 · Cited by 4
Lücke, E., Ganzert, C., Föllner, S., Wäsche, A., Jechorek, D., Schoeder, V., Walles, T., Genseke, P., & Schreiber, J. (2020) · Pneumologie · doi:10.1055/a-1199-2029 · Cited by 6
Jomrich, G., Kollmann, D., Wilfing, L., Radosavljevic, S., Ramazanova, D., Ristl, R., Grose, R. P., Ilhan‐Mutlu, A., Preusser, M., Fassnacht, C., et al. (2021) · European surgery. Supplement/European surgery · doi:10.1007/s10353-021-00700-4 · Cited by 5
Gemelli, M. T., Bidoli, P., Colonese, F., Canova, S., & Cortinovis, D. L. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s562 · Cited by 4
Venturini, N. J., Marron, T. U., Casanova-Acebes, M., Mandeli, J., Doroshow, D. B., Lucas, N., Wu, K., Hapanowicz, O., King, P. A., Hamon, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0629 · Cited by 4
Zhang, Z., Geng, X., Yin, M., Zhang, S., Liu, Y., Hu, D., & Zheng, G. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03558-4 · Cited by 3
MOLECULAR TARGETS IN LUNG CANCER: CURRENT STATUS
Imyanitov, E. N. I. (2018) · Practical oncology · doi:10.31917/1902093 · Cited by 4
Organerhalt beim fortgeschrittenen Larynx‑/Hypopharynxkarzinom: Erfahrungen aus der DELOS-II-Studie
Dietz, A., Wichmann, G., Kuhnt, T., & Wiegand, S. (2020) · HNO · doi:10.1007/s00106-020-00890-5 · Cited by 3
Zhang, L., Mai, W., Jiang, W., & Geng, Q. (2020) · Frontiers in Surgery · doi:10.3389/fsurg.2020.601805 · Cited by 3
Zhang, H., Liu, M., Du, G., Yu, B., Ma, X., Gui, Y., Cao, L., Li, X., & Tan, B. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03940-3 · Cited by 4
The oncologic efficacy of extended resections for lung cancer
Etienne, H., Kalt, F., Park, S., & Opitz, I. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27183 · Cited by 3
The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant, M. J., Woodard, G. A., & Goldberg, S. B. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.003 · Cited by 3
Metadata
- Authors
- Yang, X., Yin, R., & Xu, L.
- Affiliations
- The First People's Hospital of Changzhou (CN)
- Jiangsu Cancer Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-30
- Volume
- 379
- Issue
- 9
- Pages
- e14-e14
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2982617740
- Cited by
- 277
- References
- 8
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 25 · 2023: 65 · 2022: 40 · 2021: 49 · 2020: 49 · 2019: 28 · 2018: 7
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, lung cancer, resectable non-small cell lung cancer, immune checkpoint inhibitors, surgical resection
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Pancreatic Neoplasms, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.